The landscape of new drugs in lymphoma
Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
Permalink :
Title :
The landscape of new drugs in lymphoma
Author(s) :
Younes, Anas [Auteur]
Ansell, Stephen [Auteur]
Fowler, Nathan [Auteur]
Wilson, Wyndham [Auteur]
De Vos, Sven [Auteur]
Seymour, John [Auteur]
Advani, Ranjana [Auteur]
Forero, Andres [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Kersten Marie, Jose [Auteur]
Tobinai, Kensei [Auteur]
Zinzani Pier, Luigi [Auteur]
Zucca, Emanuele [Auteur]
Abramson, Jeremy [Auteur]
Vose, Julie [Auteur]
Ansell, Stephen [Auteur]
Fowler, Nathan [Auteur]
Wilson, Wyndham [Auteur]
De Vos, Sven [Auteur]
Seymour, John [Auteur]
Advani, Ranjana [Auteur]
Forero, Andres [Auteur]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Kersten Marie, Jose [Auteur]
Tobinai, Kensei [Auteur]
Zinzani Pier, Luigi [Auteur]
Zucca, Emanuele [Auteur]
Abramson, Jeremy [Auteur]
Vose, Julie [Auteur]
Journal title :
Nature reviews. Clinical oncology
Abbreviated title :
Nat. Rev. Clin. Oncol.
Volume number :
14
Pages :
335-346
Publication date :
2017
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, ...
Show more >The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.Show less >
Show more >The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:03:56Z